Save 20% on Press Releases and More with NNW Prime! Click to View Details
TuesdayOct 29, 2019 11:45 am

VolitionRx Ltd. (NYSE: VNRX) Starts Presentation at Dawson James Small Cap Growth Conference

VolitionRx (NYSE: VNRX) is a multi-national life sciences company focused on developing simple and easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Volition intends to expand the application of its technology beyond cancer by exploring other disease applications. For more information, visit the…

Continue Reading

TuesdayOct 29, 2019 11:20 am

Artelo Biosciences Inc. (NASDAQ: ARTL) Starts Presentation at Dawson James Small Cap Growth Conference

Artelo Biosciences (NASDAQ: ARTL) is applying exacting biopharma discipline toward developing and commercializing a diverse portfolio of novel therapeutic candidates targeting the endocannabinoid system. By leveraging past research and leading-edge, world-class science, Artelo is rapidly advancing a portfolio of endocannabinoid system modulating therapeutics. The company's broadly applicable product candidates have the potential to dramatically improve patient care in multiple major markets. Artelo expects to deliver on the promise of new therapeutic medicines to treat a wide range of diseases and conditions, creating value for patients, the medical community and investors. For more information, visit the company's website at www.artelobio.com. About NetworkNewsWire…

Continue Reading

TuesdayOct 29, 2019 11:20 am

Atossa Genetics Inc. (NASDAQ: ATOS) Starts Presentation at Dawson James Small Cap Growth Conference

Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. Atossa is developing "endoxifen" to mitigate breast cancer risk by reducing the density of breast tissue; to reduce the cancer cell activity before surgery; and to reduce the risk of recurrent or new breast cancer after the initial treatment. The company is also developing a new way to deliver therapies, such as "CAR-T" cells, through microcatheters directly to the site of breast cancer. The company believes its innovative therapies and delivery methods can transform breast cancer treatment…

Continue Reading

TuesdayOct 29, 2019 10:55 am

Fortress Biotech Inc. (NASDAQ: FBIO) Starts Presentation at Dawson James Small Cap Growth Conference

Fortress Biotech (NASDAQ: FBIO) is an innovative biopharmaceutical company identifying, in-licensing and developing high-potential clinical-stage assets. The company has over 25 programs in clinical development at Fortress, at its majority-owned and majority-controlled subsidiaries, and at entities it founded and holds significant minority ownership positions. The product candidates span six large-market therapeutic areas, including oncology, rare diseases and gene therapy, which allow it to create value while mitigating risk for shareholders. The company advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. Fortress has established partnerships with some of the world's leading academic research institutions and…

Continue Reading

TuesdayOct 29, 2019 10:55 am

CEL-SCI Corp. (NYSE: CVM) Starts Presentation at Dawson James Small Cap Growth Conference

CEL-SCI (NYSE: CVM) is at the forefront in the research and development of products for the treatment of cancer, autoimmune and infectious diseases. CEL-SCI believes that boosting a patient's immune system while still intact should provide the greatest possible impact on survival. The company's core capabilities include drug discovery, research, development and manufacturing of complex biological substances. CEL-SCI's phase 3 study is the largest phase 3 study in the world for the treatment of head and neck cancer, and after 8.5 years is very close to completion. Multikine, CEL-SCI's lead investigational therapy, is a potential therapeutic agent directed at enabling…

Continue Reading

TuesdayOct 29, 2019 10:30 am

IMAC Holdings Inc. (NASDAQ: IMAC) Starts Presentation at Dawson James Small Cap Growth Conference

IMAC Holdings (NASDAQ: IMAC) combines life science advancements with traditional medical care for movement-restricting diseases and conditions. The company owns or manages outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. IMAC Regeneration Centers provide medical services for movement-restricting conditions. It has partnered with several active and former professional athletes, including brand ambassadors Ozzie Smith, David Price, Tony Delk and Mike Ditka. IMAC's outpatient medical clinics emphasize its focus around treating sports and orthopedic injuries without surgery or opioids. For more information, visit the company's website at www.imacregeneration.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content…

Continue Reading

TuesdayOct 29, 2019 10:30 am

Dyadic International Inc. (DYAI) Starts Presentation at Dawson James Small Cap Growth Conference

Dyadic International (NASDAQ: DYAI) is a global biotechnology company developing a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large-scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is leveraging its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and…

Continue Reading

TuesdayOct 29, 2019 10:05 am

Medexus Pharmaceuticals Inc. (TSX.V: MDP) (OTCQB: PDDPF) Starts Presentation at Dawson James Small Cap Growth Conference

Medexus Pharmaceuticals (TSXV: MDP) (OTCQB: PDDPF) is a leading specialty pharmaceutical company with a strong North American commercial platform. The company's vision is to provide the best healthcare products to healthcare professionals and patients through the core values of quality, innovation, customer service and teamwork. Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics. The company's leading products are Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall™, an innovative allergy medication with a unique mode of action. For more information, visit the…

Continue Reading

TuesdayOct 29, 2019 10:05 am

Caladrius Biosciences (NASDAQ: CLBS) Starts Presentation at Dawson James Small Cap Growth Conference

Caladrius Biosciences (NASDAQ: CLBS) is a clinical-stage biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses. Caladrius currently has four programs in the mid to late stages of clinical development. The company's product candidates include three cell therapies for cardiovascular diseases that are based on its autologous CD34+ cell therapy platform, two in phase 2 testing and one in late-stage development. In addition, Caladrius has an autoimmune product candidate, CLBS03, also in phase 2 testing. Caladrius' goal is to build a broad portfolio of novel and versatile…

Continue Reading

TuesdayOct 29, 2019 9:40 am

Zynerba Pharmaceuticals Inc. (NYSE: ZYNE) Starts Presentation at Dawson James Small Cap Growth Conference

Zynerba Pharmaceuticals (NYSE: ZYNE) is the leader in pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, Autism Spectrum Disorder, 22q11.2 Deletion Syndrome (22q), and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). To meet these unmet medical needs, Zynerba is developing the next-generation transdermal cannabinoid therapeutics to improve the lives of patients. For more information, visit the company's website at www.zynerba.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000